Form 4: Cyclo Therapeutics Director William Conkling Reports Stock Grant and Disposal

Director William Conkling of Cyclo Therapeutics, Inc. reports acquisition of shares via stock grant in lieu of cash compensation and subsequent disposal.

Summary

• On August 16, 2024, William Conkling, a director of Cyclo Therapeutics, Inc., acquired 8,731 shares of common stock as a grant.
• These shares were received in lieu of cash compensation for the second quarter of 2024, under the company's non-employee director compensation policy.
• The grant was based on a closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Conkling's direct ownership changed from 33,570 to 8,731 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The director received shares as compensation, which is normal, but also disposed of a larger amount of shares, which could raise concerns.

Positives

• The director's acceptance of stock in lieu of cash may signal confidence in the company's future prospects.

Negatives

• The disposal of 33,570 shares by the director could be interpreted negatively by investors.

Risks

• Director transactions can sometimes be interpreted as a reflection of insider sentiment, and investors may react to these filings.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to monitor the buying and selling activity of company insiders.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of company performance and insider confidence.

Key Dates